Masahiko Hirata


Masahiko Hirata

J-GLOBAL         Last updated: Nov 11, 2019 at 14:28
 
Avatar
Name
Masahiko Hirata
Affiliation
Osaka University of Pharmaceutical Sciences

Research Interests

 
 

Published Papers

 
Synthesis and characterization of novel radiofluorinated probes for positron emission tomography imaging of monoamine oxidase B.
Masahiko Hirata
J Labelled Comp Radiopharm   62(9) 590-587   Jul 2019   [Refereed]
Development of a p38α-selective radioactive probe for qualitative diagnosis of cancer using SPECT.
Masahiko Hirata
Ann Nucl Med   33(5) 333-343   May 2019   [Refereed]
PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Masahiko Hirata
Bioorg Med Chem   26(8) 1609-1613   May 2018   [Refereed]
Development of novel PET probes targeting phosphatidylinositol 3-kinase (PI3K) in tumors.
Masahiko Hirata
Nucl Med Biol.   43(1) 101-107   Jan 2016   [Refereed]
Bio-imaging of hydroxyl radicals in plant cells using the fluorescent molecular probe rhodamine B hydrazide, without any pretreatment.
Masahiko Hirata
J Biosci Bioeng   118(1) 98-100   Jul 2014   [Refereed]
Relationship between uptake of a radioiodinated quinazoline derivative and radiosensitivity in non-small cell lung cancer.
Masahiko Hirata
Am J Nucl Med Mol Imaging   4(4) 293-302   Jun 2014   [Refereed]
Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
Masahiko Hirata
Biol Pharm Bull.   37(3) 355-360   Mar 2014   [Refereed]
A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline.
Masahiko Hirata
Ann Nucl Med   27(5) 431-443   Jun 2013   [Refereed]
Assessment of epidermal growth factor receptor status in glioblastomas.
Masahiko Hirata
Asia Ocean J Nucl Med Biol.   1(2) 47-52   Jun 2013   [Refereed]
Synthesis and evaluation of radioiodinated phenoxyquinazoline and benzylaminoquinazoline derivatives as new EGF receptor tyrosine kinase imaging ligands for tumor diagnosis using SPECT.
Masahiko Hirata
Ann Nucl Med   26(2) 2926-1930   Jun 2012   [Refereed]
Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
Masahiko Hirata
Bioorg Med Chem Lett.   25(2) 117-124   Mar 2012   [Refereed]
Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.
Masahiko Hirata
Ann Nucl Med   25(2) 117-124   May 2011   [Refereed]
Evaluation of radioiodinated 1-[2-(3,4-Dimethoxyphenyl)ethyl]-4-(2-iodophenylpropyl)piperazine as a tumor diagnostic agent with functional sigma receptor imaging by single photon emission computed tomography.
Masahiko Hirata
Biol Pharm Bull   31(5) 879-883   May 2008   [Refereed]
In vivo evaluation of radioiodinated 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)-piperazine derivatives as new ligands for sigma receptor imaging using single photon emission computed tomography.
Hirata M, Mori T, Soga S, Umeda T, Ohmomo Y
Biol Pharm Bull   29(10) 2009-2015   Oct 2006   [Refereed]
Synthesis and characterization of radioiodinated MD-230254: a new ligand for potential imaging of monoamine oxidase B activity by single photon emission computed tomography.
Masahiko Hirata
Chem Pharm Bull   50(5) 609-614   May 2002   [Refereed]